An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

Trial Profile

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs AZD 4547 (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Vistusertib (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms BISCAY
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Dec 2016 Planned End Date changed from 1 May 2018 to 1 Mar 2019.
    • 09 Dec 2016 Planned primary completion date changed from 1 May 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top